Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan W Riess

Showing results (71-80 of 133) with videos related to

Pageof 14
Sort By:
JTO Clinical and Research Reports|September 25, 2024
Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB StudyJonathan W Riess, Matthew S Lara, Miguel Lopez de Rodas, et al.
Clinical Lung Cancer|June 18, 2021
Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)Jonathan W Riess, Karen L Reckamp, Paul Frankel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 5, 2015
Pruritus as a Paraneoplastic Symptom of ThymomaSukhmani K Padda, Joseph B Shrager, Jonathan W Riess, et al.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2019
Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignanciesJessica A Hellyer, Matthew A Gubens, Kristen M Cunanan, et al.
Journal of Thoracic Imaging|December 9, 2017
Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial TumorsSukhmani K Padda, Donato Terrone, Lu Tian, et al.
The Oncologist|August 9, 2019
MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel <i>MET</i> R1004G MutationLisa Pei Chu, Debra Franck, Christine A Parachoniak, et al.
JCO Precision Oncology|June 4, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJonathan W Riess, Adrianus J de Langen, Santiago Ponce, et al.
Clinical Lung Cancer|November 24, 2020
Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study DesignJonathan W Riess, Paul Frankel, David Shackelford, et al.
NPJ Precision Oncology|October 29, 2025
Diversity of BRAF mutations in non-small cell lung cancer and implications on treatmentKevin Lu, John Paul Shen, Fernando J Lopez-Diaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2026
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD StudyHelena A Yu, Kwan Ho Tang, Aleksandra A Markovets, et al.
Pageof 14

Showing results (71-80 of 133) with videos related to

Sort By:
Pageof 14
JTO Clinical and Research Reports|September 25, 2024
Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB StudyJonathan W Riess, Matthew S Lara, Miguel Lopez de Rodas, et al.
Clinical Lung Cancer|June 18, 2021
Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)Jonathan W Riess, Karen L Reckamp, Paul Frankel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 5, 2015
Pruritus as a Paraneoplastic Symptom of ThymomaSukhmani K Padda, Joseph B Shrager, Jonathan W Riess, et al.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2019
Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignanciesJessica A Hellyer, Matthew A Gubens, Kristen M Cunanan, et al.
Journal of Thoracic Imaging|December 9, 2017
Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial TumorsSukhmani K Padda, Donato Terrone, Lu Tian, et al.
The Oncologist|August 9, 2019
MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel <i>MET</i> R1004G MutationLisa Pei Chu, Debra Franck, Christine A Parachoniak, et al.
JCO Precision Oncology|June 4, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJonathan W Riess, Adrianus J de Langen, Santiago Ponce, et al.
Clinical Lung Cancer|November 24, 2020
Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study DesignJonathan W Riess, Paul Frankel, David Shackelford, et al.
NPJ Precision Oncology|October 29, 2025
Diversity of BRAF mutations in non-small cell lung cancer and implications on treatmentKevin Lu, John Paul Shen, Fernando J Lopez-Diaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2026
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD StudyHelena A Yu, Kwan Ho Tang, Aleksandra A Markovets, et al.
Pageof 14